{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van Vliet VJE"],"funding":["Federation of European Microbiological Societies","Leiden University Fund","Natural Sciences and Engineering Research Council","Biotechnology and Biological Sciences Research Council"],"pagination":["5254"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12155308"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(11)"],"pubmed_abstract":["Infectious bronchitis virus (IBV) is a coronavirus first isolated in the 1930s infecting chickens. IBV causes great economic losses to the global poultry industry, as it affects egg production and causes mortality by leaving the host susceptible to secondary bacterial infections. Even though vaccines are available, they are poorly cross-protective against new variants of the virus, which are always on the cusp of emerging. Effective antiviral therapies, or possibly the production of transgenic animals immune to IBV infection, are therefore sorely needed. As the papain-like protease (PLpro) of IBV has deubiquitinating activity besides its crucial ability to cleave the viral polyprotein, we have applied a novel strategy of selecting ubiquitin variants (UbVs) from a phage-displayed library th"],"journal":["International journal of molecular sciences"],"pubmed_title":["Inhibiting Infectious Bronchitis Virus PLpro Using Ubiquitin Variants."],"pmcid":["PMC12155308"],"funding_grant_id":["BBS/E/D/20241866, BBS/E/D/20002172, and BBS/E/D/20002174","W232015-2-1","BBS/E/D/20241866","RGPIN-2020-05682","#1812"],"pubmed_authors":["Mark BL","van Vliet VJE","Kim K","Kikkert M","Roscow O","Tait-Burkard C"],"additional_accession":[]},"is_claimable":false,"name":"Inhibiting Infectious Bronchitis Virus PLpro Using Ubiquitin Variants.","description":"Infectious bronchitis virus (IBV) is a coronavirus first isolated in the 1930s infecting chickens. IBV causes great economic losses to the global poultry industry, as it affects egg production and causes mortality by leaving the host susceptible to secondary bacterial infections. Even though vaccines are available, they are poorly cross-protective against new variants of the virus, which are always on the cusp of emerging. Effective antiviral therapies, or possibly the production of transgenic animals immune to IBV infection, are therefore sorely needed. As the papain-like protease (PLpro) of IBV has deubiquitinating activity besides its crucial ability to cleave the viral polyprotein, we have applied a novel strategy of selecting ubiquitin variants (UbVs) from a phage-displayed library th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-04-08T19:29:36.462Z","creation":"2026-04-08T13:42:09.539Z"},"accession":"S-EPMC12155308","cross_references":{"pubmed":["40508063"],"doi":["10.3390/ijms26115254"]}}